A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Veverimer in Adults With CKD and Metabolic Acidosis (The REVIVE Study)
Status: Recruiting
Location: See all (14) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
The purpose of this 26 week study is is to evaluate the efficacy and safety of veverimer in treating adults with moderate-to-severe chronic kidney disease (CKD) and metabolic acidosis.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Written informed consent.
• ≥ 18 years old (male/female)).
• CKD with eGFR \< 60 mL/min/1.73m²; not expected to need dialysis/ transplant during study.
• 2 SBC values 12-21 mmol/L within 6 months pre-screening
• During screening: 2 central SBC values 12-21 mmol/L
• Willing to maintain stable diet .
• Expect to keep oral alkali therapy dose stable.
• Women of childbearing potential: negative pregnancy test and agree to abstinence or contraception.
Locations
United States
California
Academic Medical Research Institute
RECRUITING
Los Angeles
Florida
Velocity Clinical Research
RECRUITING
Edgewater
Belkis Delgado MD PA
RECRUITING
Miami Springs
ClinTrial Research - Oakwater
RECRUITING
Orlando
Georgia
Southeastern Clinical Research Institute
RECRUITING
Augusta
Idaho
CARE Institute - Boise Kidney
RECRUITING
Boise
Idaho Kidney - CARE Institute
RECRUITING
Chubbuck
CARE Institute - Idaho Falls
RECRUITING
Idaho Falls
Illinois
Research by Design
RECRUITING
Chicago
Indiana
Indiana University School of Medicine
RECRUITING
Indianapolis
Kentucky
Nephrology Associates of Kentuckiana
RECRUITING
Louisville
North Carolina
Brookview Hills Research Associates
RECRUITING
Winston-salem
New York
New York-Presbyterian Queens
RECRUITING
Fresh Meadows
Texas
Clinical Advancement Center
RECRUITING
San Antonio
Contact Information
Primary
Ayla Rasmussen
arasmussen@renibus.com
443-569-9228
Time Frame
Start Date: 2026-01-13
Estimated Completion Date: 2027-06
Participants
Target number of participants: 150
Treatments
Experimental: Veverimer
Placebo_comparator: Placebo
Related Therapeutic Areas
Sponsors
Leads: Renibus Therapeutics, Inc.